4th Novel Conjugate Summit

Date : 25th March 2025 to 27th March 2025

Place : United States of America, Boston

Website :http://go.evvnt.com/2739582-2?pid=80

Contact Person:Iwan Cleave

Description:

Pushing the Boundaries of What's Conjugatable to Assess How Novel Format and Payload Conjugates Can Deliver More Targeted and Safer Treatments to a Wider Patient Population. Time: 9:00 am to 4:30 pm. Prices: USD 2599.00 - USD 5097.00

4th Novel Conjugate Summit will be held in Boston,United States of America on date 2025-03-27

---

Deadline for abstracts/proposals : 25th March 2025

Keynote Speakers :

Conference Highlights :Home | The 4th Novel Conjugates Summit
Unite with 150+ drug developers at the only event where companies of different modality types come together to learn, collaborate and innovate

Pushing the Boundaries of What’s Conjugatable to Assess How Novel Format & Payload Conjugates Can Deliver More Targeted & Safer Treatments to a Wider Patient Population
We are witnessing a surging 83% growth of novel drug conjugates, with major collaborations betweenNurix & Pfizerfor antibody-degrader conjugates andBicycle & Novartisfor radiopharmaceuticals. With investments booming inbispecificADCs, peptide drug conjugatesandoligonucleotide conjugates, the charge is on to make iterative and incremental improvements to ADCs to pave the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.
Encompassing the landscape of these new frontiers in targeted cancer therapy, the4thNovel Conjugates Summitis returning as a one-stop shop to shine a spotlight on which novel approaches are currently being explored, what benefit each approach has, and provide a comprehensive assessment on how you can widen your conjugate design toolkit.
Join us next March to find the next hottest conjugate approach as we delve into emerging data and industry-leading discussions around novel bioconjugate design and development to redefine the future of targeted cancer therapies.
Explore how next generation payloads such asdegrader-antibody conjugatescan unlock the benefits of targeted protein degradation with a brand new pinpoint accuracy of delivery, and their potential in overcoming ADC resistance with pioneers such asPfizer,Eisai,Orum Therapeutics,NurixandTubulis.

Check the event website for more details.